This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Seung Kim | |
|---|---|
| Name | Seung Kim |
| Birth date | 1980s |
| Birth place | Seoul, South Korea |
| Nationality | South Korean / American |
| Fields | Biomedical engineering; Immunology; Chemical engineering |
| Institutions | Harvard University; Massachusetts Institute of Technology; Stanford University; Broad Institute |
| Alma mater | Seoul National University; Massachusetts Institute of Technology; Harvard Medical School |
| Known for | Nanoparticle drug delivery; T-cell engineering; Biomaterials |
Seung Kim is a biomedical engineer and immunologist noted for contributions to nanoparticle-based therapeutics, T-cell modulation, and biomaterials for targeted delivery. His work bridges translational research and clinical applications, collaborating with academic centers and biotechnology firms to advance treatments for cancer, autoimmune disorders, and infectious diseases. Kim's interdisciplinary approach integrates principles from chemical engineering, biomedical engineering, immunology, and materials science to develop platforms adopted by laboratories and industry partners worldwide.
Born in Seoul in the 1980s, Kim completed undergraduate studies at Seoul National University with a degree in chemical engineering. He pursued graduate training at the Massachusetts Institute of Technology (MIT), earning a Ph.D. in biomedical engineering while working with faculty connected to the Koch Institute for Integrative Cancer Research and collaborating with groups at the Whitehead Institute. Kim later undertook postdoctoral work at Harvard Medical School in laboratories focused on immunology and translational therapeutics, and spent visiting research periods at the Broad Institute and Stanford University.
Kim held faculty appointments at major research universities, including a tenure-track position at a United States research institution where he directed a laboratory integrating nanotechnology and cell therapy. He has served on advisory boards for biotechnology startups and small-molecule and biologics companies, and consulted for translational programs at the National Institutes of Health (NIH) and private foundations. Kim's collaborative network includes investigators at Johns Hopkins University, University of California, San Francisco, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and international partners at Cambridge University and University of Tokyo.
Kim's research centers on engineered delivery systems and cellular modulation techniques. His laboratory developed lipid- and polymer-based nanoparticles for targeted drug delivery to tumors and lymphoid organs, building on concepts established at the Koch Institute and in the field of nanomedicine. He advanced methods for in vivo reprogramming of immune cells, integrating insights from chimeric antigen receptor (CAR) research at institutions like Fred Hutchinson Cancer Center and Cleveland Clinic with biomaterials strategies pioneered at MIT and Harvard. Kim contributed to technologies enabling selective delivery of nucleic acids, small molecules, and proteins to T cells, dendritic cells, and macrophages, influencing therapeutics for non-Hodgkin lymphoma, acute myeloid leukemia, and autoimmune conditions such as rheumatoid arthritis.
Collaborations with groups at the Broad Institute and Stanford School of Medicine produced platforms for single-cell analysis and combinatorial screening, integrating tools from CRISPR technologies developed at institutions like UC Berkeley and Broad Institute. Kim's team worked with clinicians at Massachusetts General Hospital and Brigham and Women's Hospital to advance translational pipelines from preclinical models to early-phase clinical trials, aligning with regulatory frameworks overseen by the Food and Drug Administration.
Kim authored and coauthored numerous articles in high-impact journals and conference proceedings, contributing to literature alongside researchers affiliated with Nature Medicine, Science Translational Medicine, Cell, and Nature Biotechnology. His publications span nanoparticle design, immune engineering, and translational oncology. He holds multiple patents on delivery vehicles, targeting ligands, and methods for ex vivo and in vivo immune cell modulation; patent filings list collaborative inventors from institutions including MIT, Harvard, and industry partners such as Genentech and Moderna. His bibliographic record is cited by researchers at University of Oxford, Imperial College London, ETH Zurich, and leading biotech companies.
Kim received early-career awards and fellowships recognizing interdisciplinary innovation, including honors associated with organizations like the National Science Foundation, the Howard Hughes Medical Institute (HHMI) early-career programs, and institutional prizes from MIT and Harvard Medical School. He was named to lists highlighting rising investigators in biomedical engineering and translational medicine alongside peers from Stanford University and Johns Hopkins University. Kim's team secured competitive grants from agencies and foundations such as the National Institutes of Health, the Wellcome Trust, and private foundations supporting cancer research, and he was invited to present at symposia hosted by Cold Spring Harbor Laboratory and the American Association for Cancer Research.
Outside the laboratory, Kim engaged in mentorship initiatives and served on committees promoting international scientific exchange with institutions including Seoul National University and KAIST. He participated in outreach programs linking research centers such as Harvard and MIT with biotechnology incubators in Cambridge, Massachusetts and supported start-up ecosystems connected to Massachusetts Technology Collaborative and regional accelerators. Kim's legacy includes trained investigators now leading laboratories and startups at institutions like Stanford, UC San Diego, and University College London, and technologies that have been licensed to companies in the biopharmaceutical sector. His work continues to influence ongoing efforts in targeted therapeutics, immune engineering, and translational science.
Category:Biomedical engineers Category:Immunologists